Impact BioMedical (IBO) Fundamental Analysis: Revenue, Earnings & Valuation

4.61 / 10

Netural

Fundamental rating is Neutral with a 4.6/10 score. Strengths include accounts receivable turnover and interest coverage; weaknesses are fixed‑asset turnover and tax‑to‑profit ratio. Composite fund score 4.61 reflects modest upside, driven by positive Revenue‑MV, Asset‑MV and PB‑ROE factors.

Analysis Checks(7/10)

Revenue-MV

Value-5.61

Score3/3

Weight42.27%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight2.25%

1M Return0.58%

Inventory turnover ratio

Value13.46

Score3/3

Weight-2.40%

1M Return-0.67%

Accounts receivable turnover ratio

Value0.17

Score2/3

Weight-2.38%

1M Return-0.65%

PB-ROE

Value-0.72

Score1/3

Weight22.41%

1M Return5.22%

Income tax / Total profit (%)

Value17.85

Score0/3

Weight-5.40%

1M Return-1.54%

Fixed assets turnover ratio

Value3.76

Score1/3

Weight-4.45%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.68%

1M Return-0.73%

Cost of sales ratio (%)

Value1325.00

Score2/3

Weight-2.63%

1M Return-0.74%

Asset-MV

Value-0.55

Score2/3

Weight53.02%

1M Return9.91%

Is IBO fundamentally strong?

IBO scores 4.61/10 on fundamentals and holds a Fair valuation at present. Backed by its -103.88% ROE, 0.00% net margin, -5.65 P/E ratio, 4.30 P/B ratio, and 83.48% earnings growth, these metrics solidify its Netural investment rating.